MHRA backs advanced manufacturing support and gene therapy rule changes

The Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new service to support advanced manufacturing, while the government has confirmed plans to modernise the regulation of gene therapies

You need to be a subscriber to read this article.
Click here to find out more.

The MHRA has secured funding from the Office for Life Sciences (OLS) to develop and test AdvanceGxP.

MHRA backs advanced manufacturing support and gene therapy rule changes

The service will give developers earlier practical support for technologies including personalised treatments made at or near hospitals and clinics, manufacturing in space and the use of AI, robotics and automation.

These advances can raise questions about how established Good Practice standards apply. AdvanceGxP will offer access to specialist expertise to address them, helping to avoid preventable redesign and delays.

The funding will allow the MHRA to recruit a specialist team and decide how organisations will access the service, which projects will be prioritised and how it will link with existing support. Initial capacity will be limited while the approach is tested.

MHRA Chief Executive Lawrence Tallon said practical support at an early stage “can help solve problems before they cause delays, build confidence to invest and make it easier for promising new approaches to grow and scale here.” 

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
  2. You need to be a subscriber to read this article.
    Click here to find out more.
  3. You need to be a subscriber to read this article.
    Click here to find out more.

You may also like